Nov 24, 2025 9:00am EST FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Nov 20, 2025 8:00am EST FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
Nov 19, 2025 7:03pm EST FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Nov 19, 2025 8:36am EST FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Oct 31, 2025 4:30pm EDT FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Sep 12, 2025 8:30am EDT FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies
Sep 11, 2025 8:30am EDT FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment